April 10, 2020. NCHR signed on to this letter to express our grave and urgent concern for the independence of federal inspectors general.
Read More »On Health Policy
NCHR’s Comments on FDA’s Information Collection Activities on Abuse Deterrent Formulations
April 6, 2020: We support FDA’s decision to conduct a comprehensive evaluation of opioid prescribers’ knowledge, attitudes, perceptions, experiences and behaviors related to Abuse Deterrent Formulations (ADF) and agree with the FDA that new language is needed to better describe and explain ADF.
Read More »NCHR Signature on AB 1989 Opposition Letter
March 11, 2020. We oppose, unless amended AB 1989, the Menstrual Product Right to Know Act of 2020. Unlike cleaning products, less is known about the manufacture, ingredients and potential health impacts of menstrual products. People using menstrual products have the right to avoid exposures that will lead to allergic reactions.
Read More »NCHR Statement Supporting Maryland House Bill to Ban State Funds for Artificial Turf and Playgrounds
March 5, 2020. Officials in communities all over the country have been misled by artificial turf salespeople. They were erroneously told that these products are safe. But on the contrary, there is clear scientific evidence that these materials are harmful. The only question is how much exposure is likely to be harmful to which children? We should not be willing to take such a risk. Our children deserve better.
Read More »NCHR’s Comments on the Agency for Healthcare Research and Quality’s Technical Brief on Strategies for Patient, Family, and Caregiver Engagement
March 2, 2020. While we commend the Technical Brief’s aim to outline the currently available evidence on patient and family engagement strategies for managing chronic conditions, we have several suggestions.
Read More »